About bioatla inc - BCAB
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
BCAB At a Glance
BioAtla, Inc.
11085 Torreyana Road
San Diego, California 92121
| Phone | 1-858-558-0708 | Revenue | 11.00M | |
| Industry | Biotechnology | Net Income | -69,776,000.00 | |
| Sector | Health Technology | Employees | 76 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
BCAB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.611 |
| Price to Book Ratio | 2.408 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.267 |
| Enterprise Value to Sales | -1.772 |
| Total Debt to Enterprise Value | -0.043 |
BCAB Efficiency
| Revenue/Employee | 144,736.842 |
| Income Per Employee | -918,105.263 |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.128 |
BCAB Liquidity
| Current Ratio | 3.524 |
| Quick Ratio | 3.524 |
| Cash Ratio | 3.373 |
BCAB Profitability
| Gross Margin | 91.591 |
| Operating Margin | -672.209 |
| Pretax Margin | -634.327 |
| Net Margin | -634.327 |
| Return on Assets | -81.097 |
| Return on Equity | -164.301 |
| Return on Total Capital | -462.062 |
| Return on Invested Capital | -162.699 |
BCAB Capital Structure
| Total Debt to Total Equity | 5.86 |
| Total Debt to Total Capital | 5.536 |
| Total Debt to Total Assets | 1.595 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |